Skip to main content
. 2014 Mar 21;85(11):1198–1208. doi: 10.1136/jnnp-2013-307282

Figure 5.

Figure 5

(A) Percentage change from baseline in lymphocyte counts up to week 24 (all-treated analysis set). (B) The group of patients who underwent safety follow-up (discontinued treatment prematurely or did not enter the extension study). FU1, follow-up visit 1 (end of treatment + 7 days); FU2, follow-up visit 2 (end of treatment+30 days).